

| | | | | |
|---|----------------------|--------------------|------------|--|
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) | Application Number | | 10581000 | |
| | Filing Date | | 2007-05-10 | |
| | First Named Inventor | Rudiger Woscholski | | |
| | Art Unit | 1614 | | |
| | Examiner Name | | | |
| Attorney Docket Number | | 4033.3003 US | | |

| U.S.PATENTS | | | | | | |
|-------------------|---------|---------------|------------------------|------------|---|--|
| Examiner Initial* | Cite No | Patent Number | Kind Code ¹ | Issue Date | Name of Patentee or Applicant of cited Document | Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear |
| | 1 | | | | | |

If you wish to add additional U.S. Patent citation information please click the Add button.

| U.S.PATENT APPLICATION PUBLICATIONS | | | | | | |
|-------------------------------------|---------|--------------------|------------------------|------------------|---|--|
| Examiner Initial* | Cite No | Publication Number | Kind Code ¹ | Publication Date | Name of Patentee or Applicant of cited Document | Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear |
| | 1 | 20030055106 | A1 | 2003-03-20 | Faure, Robert et al. | |

If you wish to add additional U.S. Published Application citation information please click the Add button.

| FOREIGN PATENT DOCUMENTS | | | | | | | | |
|--------------------------|---------|--------------------------------------|---------------------------|------------------------|------------------|---|--|--------------------------|
| Examiner Initial* | Cite No | Foreign Document Number ³ | Country Code ² | Kind Code ⁴ | Publication Date | Name of Patentee or Applicant of cited Document | Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear | T ⁵ |
| | 1 | 00/57860 | WO | A2 | 2000-10-05 | Centre for Translational Research in Cancer, Can. | | <input type="checkbox"/> |
| | 2 | 2004/018655 | WO | A2 | 2004-03-04 | Neuronova AB, Swed. | | <input type="checkbox"/> |
| | 3 | 2 396 106 | GB | A | 2004-06-16 | Johnson & Johnson Medical Limited, UK | | <input type="checkbox"/> |

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

| | |
|------------------------|--------------------|
| Application Number | 10581000 |
| Filing Date | 2007-05-10 |
| First Named Inventor | Rudiger Woscholski |
| Art Unit | 1614 |
| Examiner Name | |
| Attorney Docket Number | 4033.3003 US |

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published. | T ⁵ |
|--------------------|---------|---|--------------------------|
| | 1 | SCHMID, Annette C., et al., "Bisperoxovanadium compounds are potent PTEN inhibitors," FEBS Letters, 566: 35-38 (2004). | <input type="checkbox"/> |
| | 2 | NOLTE, Lorraine A., et al., "A peroxovanadium compound stimulates muscle glucose transport as powerfully as insulin and contractions combined," Diabetes, 52(8): 1918-1925 (2003). | <input type="checkbox"/> |
| | 3 | BAND, Christian J., et al., "Early signaling events triggered by peroxovanadium [bpV(phen)] are insulin receptor kinase (IRK)-dependent: specificity of inhibition of IRK-associated protein tyrosine phosphatase(s) by bpV(phen)," Molecular Endocrinology, 11(13): 1889-1910 (1997). | <input type="checkbox"/> |
| | 4 | BAND, Christian J. and POSNER, Barry I., "Phosphatidylinositol 3'-Kinase and p70s6k are Required for Insulin but not Bisperoxovanadium 1, 10-phenanthroline (bpV(phen)) Inhibition of Insulin-like Growth Factor Binding Protein Gene Expression," J. Biological Chemistry, 272(1): 138-145 (1997). | <input type="checkbox"/> |
| | 5 | BARAT, Corrine and TREMBLAY, Michael J., "Treatment of Human T Cells with Bisperoxovanadium Phosphotyrosyl Phosphatase Inhibitors Leads to Activation of Cyclooxygenase-2 Gene," J. Biological Chemistry, 278(9): 6992-7000 (2002). | <input type="checkbox"/> |
| | 6 | SASAGAWA, Takahiro, et al., "Bis(6-ethylpicolinate)oxovanadium(IV) Complex with Normoglycemic Activity in KK-Ay Mice," J. Inorganic Biochemistry, 88(1): 108-112 (2002). | <input type="checkbox"/> |
| | 7 | KOZLOV, Alexander, et al., "Zeolite-encapsulated vanadium picolinate peroxo complexes active for catalytic hydrocarbon oxidations," J. Molecular Catalysis A: Chemical, 137: 223-237 (1999). | <input type="checkbox"/> |
| | 8 | POSNER, B.I., et al., "Peroxovanadium Compounds. A New Class of Potent Phosphotyrosine Phosphatase Inhibitors Which are Insulin Mimetics, J. Biol. Chem., 269 (6): 4596-4604 (1994). | <input type="checkbox"/> |
| | 9 | CUNCIC, C., et al., "Vanadate Inhibition of Protein Tyrosine Phosphatases in Jurkat Cells: Modulation by Redox State," J. Biol. Inorg. Chem., 4: 354-359 (1999). | <input type="checkbox"/> |

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

| | |
|------------------------|--------------------|
| Application Number | 10581000 |
| Filing Date | 2007-05-10 |
| First Named Inventor | Rudiger Woscholski |
| Art Unit | 1614 |
| Examiner Name | |
| Attorney Docket Number | 4033.3003 US |

| | | |
|----|--|--------------------------|
| 10 | HUYER, G., et al., "Mechanism of Inhibition of Protein-Tyrosine Phosphatases by Vanadate and Pervanadate," J. Biol. Chem., 272(2): 843-851 (1997). | <input type="checkbox"/> |
| 11 | RUMORA, L., et al., "Differential Regulation of JNK Activation and MKP-1 Expression by Peroxovanadium Complexes," Neurochem. Int., 38: 341-347 (2001). | <input type="checkbox"/> |
| 12 | SHISHEVA, A. and SHECHTER, Y., et al., "Mechanism of Pervanadate Stimulation and Potentiation of Insulin-Activated Glucose Transport in Rat Adipocytes: Dissociation from Vanadate Effect," Endocrinology, 133(4): 1562-1568 (1993). | <input type="checkbox"/> |
| 13 | WILDEN, P.A. and BROADWAY, D., "Combination of Insulinomimetic Agents H2O2 and Vanadate Enhances Insulin Receptor Mediated Tyrosine Phosphorylation of IRS-1 Leading to IRS-1 Association with the Phosphatidylinositol 3-kinase," J. Cell Biochem., 58: 279-291 (1995). | <input type="checkbox"/> |
| 14 | SHECHTER, Y., "Insulin-Mimetic Effects of Vanadate. Possible Implications for Future Treatment of Diabetes," Diabetes, 39: 1-5 (1990). | <input type="checkbox"/> |
| 15 | STEPHENS, L.R., et al., "Agonist-Stimulated Synthesis of Phosphatidylinositol(3,4,5)-Trisphosphate: A New Intracellular Signalling System?" Biochim. et Biophys. Acta, 1179: 27-75 (1993). | <input type="checkbox"/> |

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.